Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease ...

Bone marrow transplant is associated with accelerated brain aging and worse neurocognitive functioning, data suggest.

First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients with advanced penile carcinoma.

Artificial intelligence systems require consistent monitoring and staffing to put in place and to keep them working well.

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

New research suggests that, from 2011 to 2023, there was an increase in early adult mortality in the United States.

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.